Ex­clu­sive: CellFE rais­es $22M Se­ries A to ad­vance a new cell ther­a­py man­u­fac­tur­ing idea

The Cal­i­for­nia-based start­up CellFE has raised a $22 mil­lion Se­ries A to ad­vance a new ap­proach to mak­ing cell ther­a­pies with mi­croflu­idics.

Most cell ther­a­py de­vel­op­ers use hol­lowed-out virus­es to de­liv­er the ge­net­ic ed­its that make cell ther­a­pies ef­fec­tive. But those virus­es are ex­pen­sive and dif­fi­cult to man­u­fac­ture and al­so lim­it­ed in the size of what they can car­ry. CellFE CEO Al­la Za­ma­raye­va told End­points News that the com­pa­ny is try­ing a dif­fer­ent ap­proach by us­ing tiny, mi­croflu­idic chips in­stead of virus­es to mod­i­fy cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER